Ocular Therapeutix Inc

Insider sale at Ocular Therapeutix shows routine liquidity management, but a spike in social‑media buzz and weak fundamentals suggest investors should watch future sales and clinical milestones closely.

Insider sell‑to‑cover by Ocular Therapeutix COO signals routine tax compliance, not company distress; Phase‑3 results still the key driver.

Ocular Therapeutix insider sell‑to‑cover trades: 11,490 shares at $8.54, driven by tax rules, not confidence loss, amid a 25% price drop and negative P/E.

Ocular Therapeutix CFO Jason Shand buys 33,000 stock options, signalling insider confidence in the company’s growth and potential near‑term upside.